A new urine-based test has improved prostate cancer detection compared to traditional methods, says a study.
The test, developed at the University of Michigan Comprehensive Cancer Center in the US, is called Mi-Prostate Score, or MIPS. While traditional prostate cancer detection models are based on prostate serum antigen, or PSA, levels, the new method combines PSA with two markers for prostate cancer, both of which can be detected through a urine sample.
“Around 50 percent of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MIPS gives men and their doctors better information to help make those decisions,” said lead study author Scott Tomlins, assistant professor at University of Michigan Medical School.
The study looked at around 2,000 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the researchers conducted MIPS testing and compared results.
“MIPS gives men a more individualised risk assessment for prostate cancer, so that men concerned about their serum PSA levels can have a more informed conversation with their doctor about next steps in their care,” Tomlins said.
The test has been available clinically since September 2013. The findings appeared in the journal European Urology.